NEWS
You can follow the latest news of MicroViable in this section
Microviable Therapeutics announce completion of preclinical data of Human Purified Microbiota (HPMTM)
Microviable Therapeutics SL, December 22nd, 2021, a preclinical stage biotechnology company developing microbiota-based products today announced that it has completed preclinical analyses on safety and colonization capability of their unique Human Purified Microbiota (HPMTM) product. [...]
Abelardo Margolles, co-founder and scientific advisor of Microviable Therapeutics among the most cited researchers worlwide in 2021. #HighlyCitedResearchers
Recognizing the true pioneers in their fields over the last decade, demonstrated by the production of multiple highly-cited papers that rank in the top 1% by citations for field and year in the #WebOfScience™. Of the [...]
Microviable Therapeutics welcomes Ignacio Montero, PhD on board
Microviable Therapeutics welcomes Ignacio Montero, PhD on board. With a PhD in microbiology, extensive experience in R&D and a MS in Bioinformatics, Ignacio joins the team to work on the bioinformatic and genomics platform. Noteworthy, [...]
Rosa del Campo, PhD, MD joins our Scientific Advisory Board
We are excited to announce the appointment of Rosa del Campo, PhD, MD to our Scientific Advisory Board. As part of our strategic vision and further expansion, we are glad to work closely with clinicians [...]
8th International Human Microbiome Consortium Congress 2021
Microviable Therapeutics CEO Claudio Hidalgo will be presenting at the 8th International Human Microbiome Consortium Congress 2021 on June 28th. Claudio will discuss the use of "Purified microbiota and LPBs towards the therapeutic applications" and [...]
New member: Lara Dos Santos Rodríguez
Microviable Therapeutics welcomes Lara Dos Santos Rodríguez on board. Lara will performed her internships with us as part of her training to obtain the BS Biology at the University of Oviedo.